格隆汇11月6日｜百济神州(688235.SH)公告称，公司2025年前三季度营业总收入为275.95亿元，同比增 长44.2%；归属于母公司所有者的净利润为11.39亿元。主要得益于自主研发产品百悦泽®（泽布替尼胶 囊）和安进授权产品以及百泽安®（替雷利珠单抗注射液）的销售增长。此外，公司预计将于2026年上 半年针对边缘区淋巴瘤在日本递交上市申请，并有望获得孤儿药资格认定。 ...

百济神州11月6日公告，综合公司业务发展趋势，公司预计2025年实现营业收入将介于362亿元至381亿 元之间，研发、销售及管理费用合计为295亿元至309亿元，毛利率维持在80%至90%的中高位区间，全 年营业收入预计将大于营业成本、销售费用、管理费用及研发费用之总和。营业收入预计增长的调整主 要得益于百悦泽®在美国市场的领先地位以及其在欧洲和全球其他重要市场的持续扩张。 ...

北京商报讯（记者 丁宁）11月6日晚间，百济神州（688235）发布公告称，为让投资者更好地了解公司 经营业绩情况和未来业绩前景，公司决定对2025年度经营业绩预测情况进行调整，调整后2025年度营业 收入将介于362亿元至381亿元之间，研发费用、销售及管理费用合计将介于295亿元至309亿元之间。 百济神州表示，营业收入预计增长的调整主要得益于百悦泽在美国市场的领先地位以及其在欧洲和全球 其他重要市场的持续扩张。研发费用、销售及管理费用的调整主要得益于持续审慎的投资促进公司收入 和管线的增长，实现了显著的经营效率。 ...

百济神州公告，综合公司业务发展趋势，公司更新了预计的中国企业会计准则下2025年的经营业绩情 况。调整后2025年度营业收入将介于人民币362亿元至381亿元之间，较此前预测的358亿元至381亿元有 所上调。 ...

格隆汇11月6日丨百济神州(06160.HK)公布2025年第三季度业绩。2025年第三季度总收入为14亿美元， 上年同期为10亿美元，同比增40%。总收入增长主要得益于百悦泽®在美国和欧洲的销售额增长。 2025年第三季度，GAAP下毛利占全球产品收入为85.9%，上年同期为82.8%。毛利率同比取得增长，主 要因为与产品组合中的其他产品相比，百悦泽®在全球销售中占比更高。毛利率也受益于百悦泽®和百 泽安®生产效率的提高。经调整后(不含折旧及摊销)，2025年第三季度产品销售毛利率增至86.3%，而 上年同期为84.9%。 2025年第三季度，基本和稀释每股收益分别为0.09美元和0.08美元，基本和稀释每股ADS收益分别为 1.13美元和1.09美元；上年同期基本每股亏损为0.09美元，基本每股ADS亏损为1.15美元。 2025年第三季度，GAAP净利润为1.25亿美元，与上年同期亏损相比增加2.46亿美元，主要得益于收入 增长及经营杠杆改善。 ...

格隆汇11月6日丨百济神州(06160.HK)公布2025年第三季度业绩。2025年第三季度总收入为14亿美元， 上年同期为10亿美元，同比增40%。总收入增长主要得益于百悦泽®在美国和欧洲的销售额增长。 2025年第三季度，GAAP净利润为1.25亿美元，与上年同期亏损相比增加2.46亿美元，主要得益于收入 增长及经营杠杆改善。 2025年第三季度，基本和稀释每股收益分别为0.09美元和0.08美元，基本和稀释每股ADS收益分别为 1.13美元和1.09美元；上年同期基本每股亏损为0.09美元，基本每股ADS亏损为1.15美元。 2025年第三季度，GAAP下毛利占全球产品收入为85.9%，上年同期为82.8%。毛利率同比取得增长，主 要因为与产品组合中的其他产品相比，百悦泽®在全球销售中占比更高。毛利率也受益于百悦泽®和百 泽安®生产效率的提高。经调整后(不含折旧及摊销)，2025年第三季度产品销售毛利率增至86.3%，而 上年同期为84.9%。 ...

此外，百济神州2025年全年总收入指引为51亿美元至53亿美元，其中包括收入强劲增长的预期，受益于 百悦泽在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。与2024年相比，由于产品组合的 改善和生产效率的提高，毛利率预计将位于80%至90%的中高位区间。 "公司第三季度业绩持续强劲，整体营收实现卓越增长，这使得我们在全球肿瘤治疗领域的领先地位得 以进一步巩固。"百济神州联合创始人、董事长兼首席执行官欧雷强先生表示，"百悦泽如今已成为全球 BTK抑制剂领域的营收领军产品，这得益于其长期疗效和安全性数据，以及持续积累的临床证据进一步 验证了其对BTK靶点持久抑制的科学假设。与此同时，我们正在持续推进后期血液肿瘤研发管线，包括 已展现出令人瞩目的临床疗效，并有望成为同类最佳BCL2抑制剂的索托克拉;以及BTK CDAC BGB- 16673——这两款产品进一步强化了公司在慢性淋巴细胞白血病(CLL)等B细胞恶性肿瘤领域的领先优 势。凭借业内最具潜力的肿瘤管线之一，我们正蓄势待发，全力推进多项临床数据和注册里程碑的达 成，以推动公司长期价值的实现。" 公告称，总收入增长主要得益于百悦泽在美国和欧洲的销售额增长 ...

此外，百济神州2025年全年总收入指引为51亿美元至53亿美元，其中包括收入强劲增长的预期，受益于 百悦泽在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。与2024年相比，由于产品组合的 改善和生产效率的提高，毛利率预计将位于80%至90%的中高位区间。 "公司第三季度业绩持续强劲，整体营收实现卓越增长，这使得我们在全球肿瘤治疗领域的领先地位得 以进一步巩固。"百济神州联合创始人、董事长兼首席执行官欧雷强先生表示，"百悦泽如今已成为全球 BTK抑制剂领域的营收领军产品，这得益于其长期疗效和安全性数据，以及持续积累的临床证据进一步 验证了其对 BTK靶点持久抑制的科学假设。与此同时，我们正在持续推进后期血液肿瘤研发管线，包 括已展现出令人瞩目的临床疗效，并有望成为同类最佳BCL2抑制剂的索托克拉;以及BTK CDAC BGB- 16673——这两款产品进一步强化了公司在慢性淋巴细胞白血病(CLL)等B细胞恶性肿瘤领域的领先优 势。凭借业内最具潜力的肿瘤管线之一，我们正蓄势待发，全力推进多项临床数据和注册里程碑的达 成，以推动公司长期价值的实现。" 智通财经APP讯，百济神州(06160)公布2025年第 ...

格隆汇11月6日｜百济神州(6160.HK)在港交所公告，2025年第三季度总收入达14亿美元，同比增长 41%。百悦泽®（泽布替尼）该季度全球收入达10亿美元，同比增长51%。按照美国公认会计原则 (GAAP)的稀释每股美国存托股份(ADS)收益为1.09美元；非GAAP稀释每股ADS收益为2.65美元。 ...

Financial Performance - Total revenues for Q3 2025 increased by 41% to $1.4 billion compared to Q3 2024[104] - Net income for Q3 2025 was $124.8 million, a significant improvement from a net loss of $121.4 million in Q3 2024[109] - Total product revenue for the nine months ended September 30, 2025, was $3.8 billion, up 43% from $2.7 billion in the same period of 2024[109] - Net product revenue increased by 40.4% to $1,395.0 million for the three months ended September 30, 2025, compared to $993.4 million in the prior-year period, driven primarily by increased sales of BRUKINSA in the U.S. and Europe[111] - GAAP net income improved, with basic and diluted earnings per share at $0.16 and $0.15, compared to a loss of $0.36 per share in the prior-year period[140] - Adjusted net income for the nine months ended September 30, 2025, was $692,622 thousand, while the adjusted net loss for the same period in 2024 was $71,020 thousand[141] Revenue Breakdown - Global BRUKINSA revenues rose by 51% to $1.0 billion in Q3 2025 versus Q3 2024[104] - BRUKINSA global revenue totaled $1.0 billion in the third quarter, representing a 50.8% increase year-over-year; U.S. revenue for BRUKINSA was $738.7 million, a growth of 46.6%[112] - TEVIMBRA revenue totaled $190.6 million in the third quarter, reflecting a 16.7% increase compared to the prior-year period[113] - Revenue for TEVIMBRA totaled $555.3 million, representing an 18.9% increase compared to the prior-year period[127] - Net product revenue rose 43.0% to $3,805.6 million, driven by increased sales of BRUKINSA, TEVIMBRA, and Amgen products, particularly XGEVA[126] Expenses and Costs - Operating expenses increased by 10.6% to $1.05 billion in Q3 2025, driven by higher research and development costs[109] - Research and development expenses increased by 5.5% to $523.7 million for the three months ended September 30, 2025, compared to $496.2 million in the prior-year period[115] - Selling, general and administrative expenses rose by 16.2% to $528.998 million for the three months ended September 30, 2025, from $455.223 million in the prior-year period[120] - Research and development expenses increased by $119.2 million, or 8.4%, totaling $1,530.4 million for the nine months ended September 30, 2025[130] - Selling, general and administrative expenses rose by $199.8 million, or 15.1%, to $1,526.2 million, with expenses as a percentage of product sales decreasing to 40.1%[135] Cash Flow and Debt - Free cash flow for the three months ended September 30, 2025, was $354,469 thousand, significantly up from $54,714 thousand in the same period of 2024[143] - Cash, cash equivalents, and restricted cash as of September 30, 2025, totaled $4,110,542 thousand, an increase from $2,638,747 thousand as of December 31, 2024[144] - Total debt as of September 30, 2025, was $952,867 thousand, down from $1,018,013 thousand as of December 31, 2024[144] - The company paid down $75.3 million of its debt in the nine months ended September 30, 2025[144] - Total debt obligations due in the next twelve months are $813.3 million, with long-term debt obligations at $139.6 million[158] Regulatory Approvals and Developments - The FDA granted Breakthrough Therapy Designation for sonrotoclax on October 13, 2025, for treating relapsed or refractory mantle cell lymphoma[105] - The European Commission approved TEVIMBRA for neoadjuvant and adjuvant treatment of high-risk non-small cell lung cancer on August 27, 2025[107] Other Financial Metrics - Interest income, net decreased by 71.5% to $3.0 million for the three months ended September 30, 2025, from $10.6 million in the prior-year period[121] - Other expense, net was $19.0 million for the three months ended September 30, 2025, primarily due to impairment losses and foreign exchange losses[122] - Income tax expense was $22.3 million for the three months ended September 30, 2025, compared to $23.0 million in the prior-year period[123] - Gross profit for Q3 2025 was $1.22 billion, reflecting a 46.3% increase from Q3 2024[109] - Gross margin on global product sales increased to $1,198.5 million, with a gross margin percentage of 85.9% for the three months ended September 30, 2025, up from 82.8% in the prior-year period[114] - Gross margin on product sales increased to $3,279.5 million, with a gross margin percentage of 86.2%, up from 83.7% in the prior-year period[129] Market and Collaboration - A Royalty Purchase Agreement was entered into with Royalty Pharma for $885 million, related to royalty payments from Amgen's IMDELLTRA[108] - Nearly 50 abstracts were accepted for presentation at the American Society of Hematology Annual Meeting, showcasing the late-stage hematology portfolio[104] - The company expects that its operating cash flows and existing cash will fund operating expenses and planned long-term investments for at least the next 12 months[144] - As of September 30, 2025, the remaining co-development funding commitment was $183.6 million under the Amgen collaboration[161] Foreign Exchange and Market Conditions - The RMB appreciated approximately 2.5% against the U.S. dollar in the nine months ended September 30, 2025[168] - The company recognized $4.0 million in foreign exchange gains during the nine months ended September 30, 2025, compared to $2.2 million in the prior year[169]